Mesoblast Limited shares rise as Ryoncil launch puts $120 million sales target in play

Mesoblast’s stock has surged recently on the Ryoncil news. At the Oct 2 close it stood at $17.02 – up +4.6% on the day and roughly +8% from two weeks prior stockinvest.us marketbeat.com. This rally follows last week’s announcements: on Sept 26 the company announced its therapies are U.S.-origin and exempt from tariffs nasdaq.com, and on Oct 2 it disclosed that CMS has made the HCPCS J‐Code for Ryoncil permanent starting Oct 1 stocktitan.net. CEO Silviu Itescu called the new J-code “a critical element for successful commercialization of rare disease products, ensuring more efficient billing and enabling timely access to Ryoncil®” stocktitan.net.